Key points are not available for this paper at this time.
Abstract Background Elexacaftor‐tezacaftor‐ivacaftor (ETI) is a highly effective cystic fibrosis (CF) transmembrane conductance regulator (CFTR) modulating therapy for people with CF and at least one F508del variant. However, there is limited data about the safety and efficacy of this therapy in pediatric populations and in real‐world settings. This study aimed at evaluating the effectiveness, tolerability, and safety of ETI in children with CF. Methods This was a prospective observational study including all children aged 6–11 years who initiated ETI therapy between October 2022 and March 2023 at the Pediatric CF Center of Milan (Italy). Study outcomes included changes in sweat chloride concentration, FEV 1 , LCI 2.5 , body mass index (BMI), tolerance, and safety. Mean changes in study outcomes from baseline through 24 weeks were estimated using mixed‐effects regression models. Results The study included 34 children with CF (median age: 8.3 years). At Week 12, we observed an average decrease in LCI 2.5 of 2.3 units (95% confidence interval CI: −3.1; −1.5). At Week 24, sweat chloride concentration decreased by 63 mEq/L (95% CI: −69; −58), FEV 1 increased by 8.8 percentage point (95% CI: 3.7; 13.9) and BMI increased by 0.15 standard deviation scores (95% CI: 0.04; 0.25). Skin rashes appeared in 6 patients which spontaneously resolved within a few days. One month after treatment initiation, one patient experienced an elevation in liver function test results, which subsequently decreased during follow‐up visits without necessitating discontinuation of therapy. Conclusions Our data indicate that ETI therapy is well tolerated by children with CF and is effective in improving signs of lung function abnormalities from early childhood.
Daccò et al. (Thu,) studied this question.